Current Status of Targeted Therapy for Biliary Tract Cancer in the Era of Precision Medicine
Cancers · 22.02.2024 · 16 (5) · 879
DOI: 10.3390/cancers16050879 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 22.02.2024. Verfasst von Takafumi Mie und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
First-line chemotherapy has been established for advanced biliary tract cancer (BTC). However, few treatment options are available as second-line treatment. Advances in comprehensive genomic analysis revealed that nearly half of patients with BTC harbor targetable genetic alterations such as fibroblast growth factor receptor (FGFR), isocitrate dehydrogenase (IDH), BRAF, human epidermal growth factor receptor 2 (HER2), microsatellite instability (MSI)-high, neurotrophic tropomyosin receptor kinase (NTRK), rearranged during transfection (RET), and poly (adenosine diphosphate-ribose) polymerase (PARP). This review summarizes currently available options in precision medicine and clinical trials for patients with advanced BTC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.
ORCID-Profile: Takafumi Mie, Takashi Sasaki, Takeshi Okamoto, Tsuyoshi Takeda, Akiyoshi Kasuga
Zitieren
APA
Mie, T., Sasaki, T., Okamoto, T., Furukawa, T., Takeda, T., Kasuga, A., Ozaka, M., & Sasahira, N. (2024). Current Status of Targeted Therapy for Biliary Tract Cancer in the Era of Precision Medicine. Cancers, 16(5), 879. https://doi.org/10.3390/cancers16050879
Vancouver
Mie T, Sasaki T, Okamoto T, Furukawa T, Takeda T, Kasuga A, et al. Current Status of Targeted Therapy for Biliary Tract Cancer in the Era of Precision Medicine. Cancers. 2024;16(5):879. doi:10.3390/cancers16050879
BibTeX
@article{Mie2024,
author = {Mie, Takafumi and Sasaki, Takashi and Okamoto, Takeshi and Furukawa, Takaaki and Takeda, Tsuyoshi and Kasuga, Akiyoshi and Ozaka, Masato and Sasahira, Naoki},
title = {Current Status of Targeted Therapy for Biliary Tract Cancer in the Era of Precision Medicine},
journal = {Cancers},
year = {2024},
volume = {16},
number = {5},
pages = {879},
doi = {10.3390/cancers16050879}
}
EUVIMED